ABSTRACT
Purpose: Ripasudil is a class of drug which alters the trabecular meshwork to increase the aqueous outflow and has been shown to be effective in pseudoexfoliative glaucoma (PXF G). This study aimed at assessing the efficacy and safety profile of ripasudil as an adjunct treatment in patients with PXF G at maximal tolerated antiglaucoma medications. Methods: In this prospective, interventional study, 40 patients with PXF G were enrolled between May 2021 and Jan 2022. Ripasudil 0.4% was started as an adjunctive drug to the ongoing antiglaucoma medications. On follow?up visits at 1, 3, and 6 months, the visual acuity, intraocular pressure (IOP), anterior segment, and fundus findings were evaluated. The premedication and postmedication IOP values were compared by paired t?test, and a P?value <0.05 was considered statistically significant. Results: Average age at recruitment was 60.02 ± 8.74 years. Baseline premedication IOP was 25.375 ± 3.276 mmHg. IOP reduction at 6 months was found to be statistically significant in all patients, with the maximal response being 24.13%. Also, 87.5% (35/40) of patients reached target IOP or even lower IOP at the end of study. There was no statistically significant association between the PXF grade and IOP. However, the grade of inferior iridocorneal angle pigmentation was found to be higher in eyes with elevated IOP (P < 0.05). Only three patients developed conjunctival hyperemia as an adverse reaction, which was mild and transient. Conclusion: Ripasudil showed additional IOP?lowering effect with other antiglaucoma medications and exhibited no significant side effects
ABSTRACT
Introduction: Cancer chemotherapy induced diarrhea(CCID) is a frequent problem during anticancer treatment.Patho-physiology of CCID differs between chemotherapeuticagents. Neither there is specific treatment for CCID noradequate experimental models. The objective of this study wasto develop a relevant experimental animal model of CCID,which can help in development of specific therapy for CCID.Material and methods: In this study thirty six albino rats ofeither sex were divided into 6 groups of 6 animals each. GroupI rats received distilled water and served as control. GroupII,III,IV, V, VI received 5-Fluorouracil(5-FU) once intraperitoneal(IP) at doses 10,20,30,40 and 50 mg/kg respectivelyand served as test groups for experimental model of CID.Standard parameters like stool samples for quality& quantity,incidence of diarrhea, histopathology of intestine and fataloutcome in rats were recorded.Results: Out of test groups, rats treated with 5-FU 30mg/kg IP single dose developed diarrhea in 50% rats,mean timefor onset of diarrhea was 84±16.7 hours and duration was62±9.16 hours, diarrhea subsided within 7 days with mildchanges of intestinal histopathology and 16.7% mortality.Occurrence of diarrhea, change in intestinal histopathologywas not remarkable with dosage less than 30mg/kg. In 5 FU40 mg/kg & 50mg/kg group incidence of diarrhea increased to66.6% but death rate were further increased to 33.3% in5 FU40 mg/kg& 83.3% with 50mg/kg.Conclusion: The results suggest 5-FU 30mg/kg single doseIP to albino rats can be used as a suitable experimental modelfor CCID for evaluation of novel potential candidate drugs fortreatment of CCID.